Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Q32 Bio Inc. Common Stock

QTTB

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

Last trade $8.61
Day change +$0.32 (+3.86%)
Day range $8.07 – $8.70
Volume 539,694
Market cap $248M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$248.07M
Price / earnings
7.69×
Price / book
0.86×
Price / sales
4.62×
EV / sales
-0.77×
EV / EBITDA
-2.22×

Profitability

Earnings per share
$1.08
Return on assets
10.85%
Return on equity
11.21%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
56.34×
Quick ratio
56.34×
Cash ratio
56.05×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$20.07M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for QTTB, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$53.74M$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$53.74M$0$0$0$0
Selling, general and administrative$5.51M$4.86M$4.5M$4.54M$4.02M$4.01M$5.1M$3.98M
Research and development$5.15M$4.26M$3.22M$3.32M$3.56M$5.16M$7.12M$10.55M
Total operating expenses$10.66M$9.12M$7.72M$7.86M$7.58M$9.17M$12.23M$14.53M
Operating income-$10.66M-$9.12M-$7.72M$45.88M-$7.58M-$9.17M-$12.23M-$14.53M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$8.92M-$8.95M-$7.61M$57.73M-$7.39M-$9.49M-$11.03M-$14.17M
Income taxes$0$0$0$0$0$0$0$21K
Net income-$8.92M-$8.95M-$7.61M$57.73M-$7.39M-$9.49M-$11.03M-$14.19M
Net income attributable to common shareholders-$8.92M-$8.95M-$7.61M$57.73M-$7.39M-$9.49M-$11.03M-$14.19M
EBITDA-$10.58M-$9.03M-$7.63M$45.97M-$7.49M-$9.08M-$12.11M-$14.41M
Basic earnings per share-$0.26-$0.44-$0.54$4.59-$0.60-$0.78-$0.90-$1.16
Diluted earnings per share-$0.26-$0.44-$0.54$4.57-$0.60-$0.78-$0.90-$1.16

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Why Is Q32 Bio Stock Gaining Friday?

Q32 Bio (NASDAQ: QTTB) announced a $55 million private placement, issuing 6.725 million shares at $8 per share to fund development of therapies for alopecia areata and immune-mediated diseases. The stock gained 9.84% on Friday, trading at $11.32, supported by strong technical momentum with a golden cross formation and analyst consensus rating of Strong Buy with a $13.50 price target.

Benzinga

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront payments, with potential milestone payments up to $592 million, causing its stock to surge by over 115%.

Benzinga

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Soligenix, Inc. (NASDAQ: SNGX) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA. Longeveron Inc. (NASDAQ: LGVN) surged 54% to $2.6350 following insider buys from multiple company executives. SuperCom Ltd. (NASDAQ: SPCB) shares gained 39.4% to $0.3849 after jumping around 18% on Friday. Piedmont Lithium Inc. (NYSE: PLL) shares gained 32.1% to $16.75 following a 5% decline on Friday. Snap One Holdings Corp. (NASDAQ: SNPO) surged 31.6% to $10.71 after the company announced that it will be acquired by Resideo Technologies. Organovo Holdings, Inc. (NASDAQ: ONVO) shares surged 30.9% to $1.32 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo. Kuke Music Holding Limited (NASDAQ: KUKE) jumped 27% to $2.7650. HUB Cyber Security Ltd. (NASDAQ: HUBC) gained 24% to $1.61 after gaining over 11% on Friday. Edgio, Inc. (NASDAQ: EGIO) gained 24% to $22.18. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.